ELTX

Elicio Therapeutics, Inc.

Recommendation Details

PortfolioMicrocap Short

DateOct 30, 2026

ForecastQ Daily Probabilities

46.5%

71.2%

63.8%

Company Description

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Recent News & Events

Near-term catalysts skew positive on fresh ESMO/Nature Medicine Phase 2 subgroup data and a Q4 2026 Phase 1 trial initiation, but a thin cash runway into Q1 2027 and prior primary-endpoint miss keep risk elevated.

Clinical Data Readout

Late-breaking AMPLIFY-7P subgroup data at ESMO 2026

Elicio presented late-breaking Phase 2 AMPLIFY-7P results at ESMO Congress 2026 with simultaneous publication in Nature Medicine. Although the ITT primary DFS endpoint was missed (HR 0.85), pre-specified subgroup analyses favored camupepimut (ctDNA-negative HR 0.51; ctDNA-positive HR 0.57; no prior radiation HR 0.59; multivariable adjusted HR 0.47, p=0.0086), which may support a refined Phase 3 path and could lift sentiment after the June 2026 selloff.

Elicio Therapeutics Press Release

Clinical Trial Initiation

Phase 1 combination trial initiation anticipated Q4 2026

Elicio has guided to initiating a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic mKRAS pancreatic cancer in Q4 2026. Confirmation of initiation within the current quarter would be a near-term positive catalyst validating the platform beyond the adjuvant setting.

SEC Filing (Q2 2026 Earnings Release)

Regulatory/Development Update

FDA discussions to inform potential Phase 3 design

Elicio plans to discuss the totality of AMPLIFY-7P findings with the FDA to inform a potential Phase 3 study in adjuvant pancreatic cancer, including ctDNA-based stratification and combination strategies. Any disclosed FDA feedback or Phase 3 design announcement would be a meaningful near-term catalyst, though timing is uncertain and subject to regulatory discussion.

Elicio Therapeutics Press Release

Going Concern / Financing Risk

Cash runway into Q1 2027 raises financing overhang

Following a $15 million July 2026 registered direct offering, Elicio states cash runway extends only into Q1 2027, and its 10-Q flags substantial doubt about ability to continue as a going concern. This creates persistent dilution/financing overhang that could cap upside and pressure shares on any negative data or delay.

SEC Filing (Q2 2026 Earnings Release)

Conference Presentation

AMPLIFY-7P results to be presented at SITC 2026

Elicio is scheduled to present Phase 2 AMPLIFY-7P results at the SITC 2026 Annual Meeting. Additional translational/immunogenicity detail at this forum could reinforce the subgroup narrative and act as a modest near-term sentiment catalyst.

Elicio Therapeutics Press Releases

ELTX

ELTX

Company Information

Recommendation Details

Company Description

Recent News & Events

Late-breaking AMPLIFY-7P subgroup data at ESMO 2026

Phase 1 combination trial initiation anticipated Q4 2026

FDA discussions to inform potential Phase 3 design

Cash runway into Q1 2027 raises financing overhang

AMPLIFY-7P results to be presented at SITC 2026